Drug Trial Radar · NCT05425472
A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer
Last checked: Nov 19, 2026Latest source record: Sep 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 27, 2022
Primary completion
Jan 30, 2023
Study completion Mar 30, 2023
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy, safety and pharmacokinetic characteristics of HR070803 in the treatment of advanced esophageal cancer.
Conditions
- Advanced Esophageal Cancer
Interventions
HR070803Drug
HR070803
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: for 4 months following the date the last patient was randomized
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.